Table 1.
Relationship between immunoreactivity of FOXP1 and clinicopathological findings in invasive breast cancer (n = 133)
| Clinical findings | Immunoreactive score of FOXP1a | |||
|---|---|---|---|---|
| Positive (n = 89) | Negative (n = 44) | P value | ||
| Ageb (mean ± SD) | 57 ± 15 | 61 ± 13 | ||
| Age | ≤50 | 26 (19.5%) | 13 (9.8%) | 0.97 |
| 50< | 63 (47.4%) | 31 (23.3%) | ||
| Menopause | Pre | 27 (20.3%) | 11 (8.3%) | 0.52 |
| Post | 62 (46.6%) | 33 (24.8%) | ||
| Lymph node | Positive | 23 (21.3%) | 18 (16.7%) | 0.40 |
| Negative | 43 (39.8%) | 24 (22.2%) | ||
| pT | ≤20 mm | 37 (33.0%) | 33 (29.5%) | 0.014 |
| 20 mm< | 32 (28.6%) | 10 (8.9%) | ||
| Stage | I and II | 80 (60.1%) | 43 (32.3%) | 0.21 |
| III and IV | 9 (6.8%) | 1 (0.8%) | ||
| Grade | I | 33 (30.8%) | 12 (11.2%) | 0.015 |
| II and III | 31 (29.0%) | 31 (29.0%) | ||
| ER | Positive (PS ≥ 3) | 68 (51.1%) | 23 (17.3%) | 0.0048 |
| Negative (PS ≤ 2) | 21 (15.8%) | 21 (15.8%) | ||
| PgR | Positive (PS ≥ 3) | 44 (33.1%) | 13 (9.8%) | 0.029 |
| Negative (PS ≤ 2) | 45 (33.8%) | 31 (23.3%) | ||
| HER2 | Positive | 30 (25.6%) | 18 (15.4%) | 0.64 |
| Negative | 46 (39.3%) | 23 (19.7%) | ||
All other values represent the number and proportion of cases
ER estrogen receptor, PgR progesterone receptor, PS proportion score
aFOXP1 immunoreactive scores of 0, 2 and 3–8 were defined as negative and positive immunoreactivity, respectively
bData are presented as mean ± SD